A noninvasive method for molecular imaging of the activity of different signal transduction pathways and the expression of different genes in vivo would be of considerable value. It would aid in understanding the role specific genes and signal transduction pathways have in various diseases, and could elucidate temporal dynamics and regulation at different stages of disease and during various therapeutic interventions. We developed and assessed a method for monitoring the transcriptional activation of endogenous genes by positron-emission tomography (PET) imaging. The HSV1-tk͞GFP (TKGFP) dual reporter gene was used to monitor transcriptional activation of p53-dependent genes. A retrovirus bearing the Cis-p53͞TKGFP reporter system was constructed in which the TKGFP reporter gene was placed under control of an artificial cis-acting p53-specific enhancer. U87 glioma and SaOS-2 osteosarcoma cells were transduced with this retrovirus and used to establish xenografts in rats. We demonstrated that DNA damage-induced up-regulation of p53 transcriptional activity correlated with the expression of p53-dependent downstream genes, such as p21, in U87 (wild-type p53), but not in SaOS-2 osteosarcoma (p53 ؊͞؊) cells. We showed that PET, with [ 124 I]FIAU (2-fluoro-2-deoxy-1-␤-D-arabinofuranosyl-5-[ 124 I]iodouracil) and the Cis-p53TKGFP reporter system, is sufficiently sensitive to image the transcriptional regulation of genes in the p53 signal transduction pathway. These imaging results were confirmed by independent measurements of p53 activity and the expression levels of downstream genes (e.g., p21) by using conventional molecularbiological assays. PET imaging of p53 transcriptional activity in tumor xenografts by using the Cis-p53TKGFP reporter system may be useful in assessing novel therapeutic approaches.
I
n the original paper by Tjuvajev et al. (1), we described a paradigm for noninvasive imaging of transgene expression that requires the appropriate combination of ''reporter gene'' and ''reporter substrate.'' The reporter gene product (an enzyme) selectively converts a reporter substrate to a metabolite that is trapped within the transduced cell. This imaging paradigm is an in vivo radiotracer enzyme assay, and it can be used to image the expression and regulation of different endogenous genes and signal transduction pathways. We established and validated model systems in tissue culture and in experimental animals by using HSV1-tk (herpes simplex virus type 1 thymidine kinase) as a reporter gene and radiolabeled 2Ј-fluoro-2Ј-deoxy-1-␤-Darabinofuranosyl-5-iodouracil (FIAU) as a reporter substrate (1) . Highly specific images of HSV1-tk expression in experimental animal tumors were obtained noninvasively by using radioiodinated [ 131 I]FIAU and a clinical ␥ camera system (2-4), or [ 124 I]FIAU and positron-emission tomography (PET) (5) . Similar results have been demonstrated using 18 F-labeled acycloguanosine analogues, such as 8-fluoro-ganciclovir (6), 8-fluoropenciclovir, (7) and 9-[(3-f luoro-1-hydroxy-2-propoxy)-methyl]guanine and 9-(4-fluoro-3-hydroxymethylbutyl)guanine (8) as reporter substrates and wild-type or mutant HSV1-tk as the reporter gene (8) . Also, we demonstrated that HSV1-tk imaging could be used to monitor and quantitatively assess the expression of a second gene that is cis-linked to the reporter gene by an internal ribosome entry site (IRES) sequence (4) . This observation was subsequently confirmed by other investigators (9) .
In this paper we assess the feasibility of PET to image the transcriptional activation of p53-dependent genes in vivo. We selected the p53 tumor suppressor gene as a model gene for our imaging studies because it is the most commonly mutated gene in human cancer (10, 11) . Studies were performed using two different human tumor xenograft models in rats. These included the U87 human glioma that expresses wild-type p53 (12) and the SaOS-2 osteosarcoma that has a deletion of the p53 gene in both alleles (13) . Both tumor cell lines were transduced with retrovirus bearing the Cis-p53͞TKGFP reporter system in which the TKGFP reporter gene is placed under control of an artificially constructed cis-acting p53-specific enhancer. We demonstrated that DNA damage-induced up-regulation of p53 transcriptional activity can be imaged and correlates with the expression of p53-dependent downstream genes, such as the p21, in Cis-p53͞ TKGFP-transduced U87 glioma cells. We show that upregulation of p53 can be monitored by fluorescent microscopy in vitro and in situ, and by PET imaging of xenografts in vivo. This was accomplished by using a dual-modality reporter gene, TKGFP, which is a fusion between the HSV1-tk and eGFP (enhanced green fluorescent protein) genes (14) .
Materials and Methods
Generation of Cis-p53͞TKGFP and TKGFP Reporter Vectors. We have described the TKGFP fusion gene and generation of the TKGFP reporter vector (14) . For Cis-p53͞TKGFP reporter vector, TKGFP cDNA was obtained from the plasmid pTKGFP (14) and placed into the plasmid p53-Luc (Stratagene) (15) , replacing the luciferase gene under control of 15 tandem repeats of -TGC-CTGGACTTTGCCTGG-sequence that contains two p53-specific binding sites (underlined) (15) . Briefly, the luciferase gene located between the EcoRI and XbaI sites was removed from the p53-Luc plasmid, the EcoRI end was blunted, and the NheI-XbaI fragment from the plasmid pTKGFP containing the TKGFP fusion gene with a blunted NheI end was ligated with the p53-Luc backbone. The BamHI-NotI fragment was taken from the resulting plasmid containing the p53 enhancer element, TATA-box, and the TKGFP fusion gene, and placed into the multiple-cloning site of the retroviral vector pLXSN (CLON-TECH) 5Ј to the neomycin-resistance gene that is under control of the simian virus 40 promoter. The NheI-NheI fragment This paper was submitted directly (Track II) to the PNAS office.
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containing the pBR322 backbone (which is a part of the pLXSN vector) and most of the viral 3Ј long terminal repeat (LTR) was replaced with the same fragment from the Moloney murine leukemia virus retroviral vector dSFG-Ntp (16) containing the pUC19 backbone and a crippled 3ЈLTR. The resulting plasmid termed DXS53TGN is shown in Fig. 1A. DXS53TGN was transfected into the H29 transient retroviral producer cell line (17) . After transfection of H29 cells, the tetracycline block was removed to allow for retroviral vector production. The Cis-p53͞ TKGFP retrovirus-containing medium was collected for 4 consecutive days and stored at Ϫ80°C. (17) was maintained in DMEM supplemented with 10% FCS, puromycin (2 g/ml), and tetracycline (1 g/ml). The U87 and SaOS cells were transduced with the Cis-p53͞TKGFP vector by incubating 50% confluent tumor cell cultures with the vector-containing medium for 12 h in the presence of hexadimethrine bromide (8 g/ml). Mixed populations of transduced U87p53͞TKGFP and SaOSp53͞TKGFP cells were obtained by selection in corresponding media supplemented with 500 g/ml of G418 (Life Technologies). The RG2TKGFP cells that constitutively express TKGFP reporter gene were described (14) .
Selection of Transduced Tumor Cell Clones. Single cell-derived clones of transduced U87p53͞TKGFP and SaOSp53͞TKGFP tumor cells with optimal properties for the reporter system (low background and high inducibility), were obtained by using fluorescence-activated cell sorting (FACS). Clones with very low background fluorescence were obtained and propagated in duplicate 96-well plates. The clones in one plate were treated with N,NЈ-bis(2-chloroethyl)-N-nitrosourea (BCNU; 40 g/ml) for 2 h to activate the p53 pathway as described elsewhere (18) . After the BCNU treatment, the clones were assessed for TKGFP fluorescence by microscopy every hour, and the brightest fluorescing clones were selected. The fluorescence intensity in the selected clones was quantified by FACS. Clones with the lowest background and the highest BCNU-inducible fluorescence were selected and propagated further. The background and BCNUinducible TKGFP fluorescence was reassessed after expansion in each clone, and a clone with optimal characteristics was selected and used in further experiments. Reverse Transcription (RT)-PCR for TKGFP and p21. For TKGFP, the specific HSV1-tk primers were 5Ј-ATGGCT TCGTAC-CCCTG-3Ј and 5Ј-AAGGTCGGCGGGATGAG-3Ј. For p21, a commercial primer kit was used (Stratagene, catalog no. . This vector has a mutation in the 3ЈLTR that renders the silencing of its promoter activity after duplication as 5ЈLTR during integration. The expression of the TKGFP gene is regulated by an artificial promoter containing multiple tandem repeats of a p53-specific DNA-binding motif. Constitutive expression of the neomycin-resistance gene (Neo) is driven by the simian virus 40 early immediate promoter, allowing for the selection of stably transduced cells. Fluorescence microscopy and fluorescence-activated cell sorting (FACS) analysis of a transduced U87p53͞TKGFP cell population in the noninduced (control) state (B and C), and 24 h after a 2-h treatment with N,NЈ-bis(2-chloroethyl)-N-nitrosourea (BCNU) at 40 g/ml (D and E). (F) Immunoblot analysis for total p53, activated p53 (Ser15 phosphorylated), p21, and TKGFP protein levels in U87p53͞TKGFP cells in the noninduced state (0) and after treatment with different doses of etoposide (5-40 g/ml), 40 g/ml BCNU, or 400 mJ of UV radiation. (G) Reverse transcription (RT)-PCR analysis for p21 and TKGFP mRNA levels performed in the same samples as shown in F. The levels of phospho-p53, total p53, p21, and TKGFP proteins increase after etoposide treatment in a dose-dependent manner; similar increases were observed for BCNU and UV treatments (data not shown). (H) TKGFP expression in different cell populations as measured by the radiotracer assay. The FIAU͞thymidine (TdR) ratio is low in wild-type U87 cells (negative control) and in noninduced U87p53͞TKGFP cells. In contrast, BCNU-treated U87p53͞TKGFP cells had a significantly higher FIAU͞TdR accumulation ratio (higher TKGFP expression), which was within the range observed in RG2TKGFP cells that constitutively express TKGFP. Studies were conducted when the tumors were Ϸ15 mm in diameter. Generation of SaOS and SaOSp53TKGFP xenografts in rnu͞rnu rats was unsuccessful, and is consistent with previous reports (13) .
[ 124 I]FIAU Synthesis.
124
I was produced on a CS-15 cyclotron employing the (p, n) nuclear reaction in an enriched tellurium-124 oxide target. After irradiation, the target was subjected to dry distillation to release the trapped radioiodide, and 124 I was isolated in a small volume of phosphate buffer as described (20) . No-carrier-added synthesis of [ 124 I]FIAU was performed with a stannylated precursor, 2Ј-fluoro-2Ј-deoxy-1-␤-D-arabinofuranosyl-5-(tri-n-butyltin)-uracil (FTBSnAU), which was allowed to react with NaI[ 124 I] in the presence of a mixture of acetic acid and 30% hydrogen peroxide. After quenching with sodium metabisulfite, the [ 124 I]FIAU was isolated on a C-18 Sep-Pak cartridge system, and eluted with methanol. After evaporation of methanol, the product was reconstituted in a sterile, pyrogenfree, physiological saline (with 5% ethanol added) and passed through a sterile 0.22-m filter (Millipore). The radiochemical purity was determined by radio-TLC (Sigma-Aldrich silica gel plates, eluent: ethyl acetate͞acetone͞water 14:8:1; [ 124 I]FIAU exhibiting an R f of 0.61). Radio-TLC plates were analyzed with a System 200 Scanner equipped with an Auto Changer 1000 (BioScan, Inc., Washington, DC). The radiochemical purity was 97 Ϯ 2%; [ 124 I]iodide was the only contaminant. The specific activity of the initial 124 I was found to be Ͼ30 Ci/mmol (1 Ci ϭ 37 GBq) (20) , so that the specific activity of [ 124 I]FIAU was estimated to be close to this value.
PET Imaging and Quantitation. One day before [ 124 I]FIAU administration, the animals received a 2-ml i.p. injection of a 0.9% NaI solution to block the thyroid uptake of radioactive iodide (small amounts of contaminant). [ 124 I]FIAU was administered i.v., 300 Ci per animal. PET imaging was performed on an Advance PET tomograph (General Electric) 24 h after tracer administration to allow for sufficient clearance of body background radioactivity. The 24-h biological clearance improved the signalto-noise ratio and specificity of the images.
Animals were anesthetized by i.p. injection of ketamine (87 mg/kg) and xylazine (13 mg/kg). Transmission and emission scans were obtained in two-dimensional mode; the emission scans were corrected for random counts, dead time, and attenuation. The duration of the transmission and emission scans was 15 and 45 min, respectively. Images were reconstructed by using an iterative reconstruction algorithm (5), yielding slice thickness of 4.2 mm and a transaxial resolution element size of 4 mm 2 . Radioactivity concentration in tumors (% dose per g) was measured from the PET images as described (5) .
To estimate tumor dosimetry of [ 124 I]FIAU and to confirm the PET radioactivity measurements, the individual tumors, muscle, and venous blood were sampled, weighed, and assayed for 124 I radioactivity by using a Packard 5500 ␥ spectrometer. A portion of each tumor tissue sample was used for the assessments of p21 and TKGFP gene expression with RT-PCR. The cryosections of the remaining portion of each tumor sample were used to assess p53 activity status and p21 expression with immunohistochemistry, and TKGFP expression with fluorescence microscopy.
Immunohistochemistry for p21 and Activated p53. Anti-p21͞WAF mouse monoclonal antibody F-5 (Santa Cruz Biotechnology) and anti-phospho-p53(15Ser) rabbit polyclonal antibody (BioLabs, NJ) were used as primary antibodies in combination with the anti-mouse and anti-rabbit Vectastain Elite ABC immunohistochemistry kits (Vector Laboratories). Counterstaining was performed with eosin.
Results

Characterization of the Selected U87p53͞TKGFP and SaOSp53͞TKGFP
Clones in Vitro. U87p53͞TKGFP and SaOSp53͞TKGFP cells were seeded into 150 ϫ 25 mm plates and grown until 60% confluent. The cells were then exposed to media with different concentrations of etoposide (5-40 g/ml), BCNU (0.1-100 g/ml), or to UV (50-800 mJ), and assessed every hour for p53 pathway induction by monitoring TKGFP expression with fluorescence microscopy and FACS. There was some background p53 activity (TKGFP fluorescence) in a few of the nontreated U87͞Cis-p53͞TKGFP cells that was probably cell cycleassociated ( Fig. 1 B and C) . Two peaks of TKGFP expression were observed: one at 4-6 h and another at about 24 h after induction with etoposide, BCNU, or UV (data not shown).
U87p53͞TKGFP cells were also assessed for activation of the p53 pathway and for TKGFP expression 24 h after exposure to different concentrations of etoposide (5-40 g/ml) or BCNU (40 g/ml) for 2 h, or exposed to UV (400 mJ). U87p53͞TKGFP cells treated with 40 g/ml of etoposide or 40 g/ml BCNU for 2 h, or those that received 400 mJ of UV radiation, had optimal activation of the p53 signaling pathway and levels of TKGFP expression (Fig. 1, D and E) . Significant increases in p53 phosphorylation and total p53 protein expression were observed (Fig. 1F) . Increased p53 activity caused up-regulation of p21 and TKGFP gene expression, as manifested by increases in corresponding mRNA (Fig. 1G ) and protein levels (Fig. 1F) . Increased TKGFP mRNA and protein levels in BCNU-treated U87p53͞TKGFP cells corresponded with significantly higher levels of [ Figs. 2A and 3) , whereas substantial accumulation was observed in RG2TKGFP (positive control) xenografts (Figs.  2B and 3) . In animals treated with BCNU (40 mg/kg i.p.), a significantly higher accumulation of [ 124 I]FIAU was observed in U87p53͞TKGFP xenografts as compared with wild-type U87 xenografts ( Fig. 2C and 3 ; P Ͻ 0.05, paired t test), and as compared with nontreated U87p53͞TKGFP xenografts (Figs. 2 A-C and 3; P Ͻ 0.05, unpaired t test). These results indicate that BCNU-induced activation of the p53 signal transduction pathway in U87p53͞TKGFP xenografts can be imaged with PET.
[ 124 I]FIAU clearance from blood was somewhat slower in BCNU-treated animals, as reflected by the higher and more variable 24-h plasma levels (Fig. 3A) . This difference in plasma clearance is most likely related to BCNU toxicity and is reflected in muscle and wild-type U87 tissue levels as well. Therefore, the xenograft-to-muscle radioactivity ratio was calculated to normalize the data to body background activity. BCNU treatment also had a significant negative effect on the constitutive expression of TKGFP in the RG2TKGFP xenografts (positive control).
Fluorescent microscopic analysis of tumor tissue sections from the animals that were imaged with PET demonstrated a low incidence of fluorescing (TKGFP expressing) cells in nontreated U87p53TKGFP xenografts (Fig. 4A) . In contrast, the U87p53TKGFP xenografts from the animals that were treated with BCNU had a high density of fluorescing cells (Fig. 4B ) that was comparable to that in the RG2TKGFP xenografts (positive control).
As compared with nontreated U87p53͞TKGFP xenografts, BCNU-treated U87p53͞TKGFP xenografts had increased phospho-p53 and total p53 protein levels, increased p21 and TKGFP mRNA, and corresponding protein levels (Fig. 4 C and D) . Immunohistochemical analysis of tumor tissue sections demonstrated increased density of both the phospho-p53-positive cells and p21-positive cells in BCNU-treated U87p53͞TKGFP xenografts as compared with nontreated U87p53͞TKGFP xenografts. Both, the phospho-p53-and p21-positive immunohistochemical staining colocalized with TKGFP-fluorescing cells (data not shown).
Discussion
The development of methods that allow imaging at the molecular-genetic level or allow visualization of different steps in various signal transduction pathways is a new research endeavor. However, there are practical limitations to the development of large numbers of unique probes for direct imaging of each gene or each step of different signal transduction pathways. These and other limiting factors stimulated the development of several reporter gene-based assay systems. These reporter systems can monitor the regulation of gene expression at the level of transcription (21, 22) or posttranscription (23) , can monitor the activity of different transcription factors (24) , and can assess protein-protein interactions in different signal transduction pathways (24) . In our opinion, a more reasonable approach would be to develop imaging methods that use one (or a few) well-characterized probes for reporter gene-based systems that allow for the detection and quantitation of different molecularbiological processes.
We selected the p53 gene as a model gene for in vivo molecular-genetic imaging studies. The p53 tumor suppressor is the most commonly mutated gene in human cancer (10, 11) . In normal cells under physiological conditions, the tumorsuppressive p53 protein is expressed at low concentrations and has a short half-life because of rapid turnover due to ubiquitination and proteolysis (26) . p53 becomes stabilized and activated in response to a number of stressful stimuli, including exposure to DNA-damaging agents, hypoxia, nucleotide depletion, or oncogene activation (22) . The activation of p53 allows it to carry out its function as a tumor suppressor through a number of growth-controlling endpoints (27) . These endpoints include cell cycle arrest, apoptosis, senescence, differentiation, and antiangiogenesis (27) . In its role as a tumor suppressor, p53 serves as a ''guardian'' of the genome and a ''gatekeeper'' for growth and division, by regulating critical checkpoints in response to the distinct stress stimuli (11, 27) .
In this paper we describe the results of a merger between one of the molecular-biologic reporter-gene based systems, the cisreporter system (21, 22) , and an established method for noninvasive imaging of HSV1-tk reporter gene expression with [ 124 I]FIAU and PET (1) (2) (3) (4) (5) . A recently developed dual-modality reporter gene, TKGFP (14) , was used in these studies to provide additional optical (fluorescence) imaging and FACS analysis data. The TKGFP gene was introduced into the retroviral reporter vector and placed under the control of a p53-specific enhancer element, so that TKGFP reporter gene expression would be transcriptionally up-regulated along with several other endogenous genes upon activation (phosphorylation) of p53 protein by different signal transduction pathways. A significant increase in TKGFP expression over the baseline was observed in U87p53͞TKGFP cells treated with known activators of p53 pathway (BCNU, etoposide, and UV radiation). A biphasic pattern of p53 activation after BCNU induction observed at 4-6 h and at about 24 h is in agreement with reported data (23, 28) . Fig. 3 . Tissue radioactivity and tissue-to-muscle ratios. Two groups of animals are compared; nontreated (solid bars, n ϭ 6) and BCNU-treated (40 mg/kg, i.p., shaded bars, n ϭ 6). Tissue radioactivity (% dose/g; A) and the tissue-to-muscle radioactivity ratio (B) are shown; error bars are Ϯ SD. Significant differences between BCNU-treated and nontreated animals (unpaired t test, P Ͻ 0.05) are indicated by * . Significant differences between the test (U87p53TKGFP) and negative control (U87wt) xenografts (paired t test, P Ͻ 0.05), in either BCNU-treated or nontreated animals, is indicated by †. 
